Cargando…

Efficiency of low dosage apatinib in post-first-line treatment of advanced lung adenocarcinoma

Chemotherapy is the standard treatment of in advanced lung adenocarcinoma patients without driver mutation. However, few drugs could be selected when diseases progressed after second-line treatment. As a small molecule inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2), apatinib wa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zeng, Da-Xiong, Wang, Chang-Guo, Lei, Wei, Huang, Jian-An, Jiang, Jun-Hong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5630408/ https://www.ncbi.nlm.nih.gov/pubmed/29029508 http://dx.doi.org/10.18632/oncotarget.19908

Ejemplares similares

Apatinib in the treatment of advanced lung adenocarcinoma with KRAS mutation
por: Zeng, Da-xiong, et al.
Publicado: (2017)

Apatinib as post second-line therapy in EGFR wild-type and ALK-negative advanced lung adenocarcinoma
por: Fang, Shen-Cun, et al.
Publicado: (2017)

Safety and Efficacy of Low-Dosage Apatinib Monotherapy in Advanced Lung Squamous-Cell Carcinoma: A Prospective Cohort Study
por: Geng, Qian, et al.
Publicado: (2020)

Concurrent apatinib and docetaxel vs apatinib monotherapy as third- or subsequent-line therapy for advanced gastric adenocarcinoma: a retrospective study
por: Lin, Haimin, et al.
Publicado: (2019)

Evaluation of calculating carboplatin dosage in carboplatin–pemetrexed therapy as the first‐line therapy for Chinese patients with advanced lung adenocarcinoma
por: Zhu, Yixiang, et al.
Publicado: (2018)

Apatinib as non-first-line treatment in patients with Intrahepatic Cholangiocarcinoma
por: Mao, Jinzhu, et al.
Publicado: (2021)

Low-dose apatinib monotherapy in advanced chemotherapy-refractory small cell lung cancer: a case series and literature review
por: Liu, Ying-ying, et al.
Publicado: (2019)

Impact of apatinib in combination with osimertinib on EGFR T790M-positive lung adenocarcinoma
por: Liu, Yang, et al.
Publicado: (2019)

Combination of apatinib mesylate and second-line chemotherapy for treating gastroesophageal junction adenocarcinoma
por: Lu, Bin, et al.
Publicado: (2019)

Prolonged response to first-line erlotinib for advanced lung adenocarcinoma
por: Copeman, Michael
Publicado: (2008)

Apatinib as first-line treatment in patients with advanced hepatocellular carcinoma: a phase II clinical trial
por: Hou, Zhenyu, et al.
Publicado: (2020)

Efficacy of apatinib combined with FOLFIRI in the first-line treatment of patients with metastatic colorectal cancer
por: Rong, Xuetong, et al.
Publicado: (2022)

Apatinib combined with S-1 as second-line therapy in advanced gastric cancer
por: Qiu, Zhi-Yuan, et al.
Publicado: (2021)

First-line albumin-bound paclitaxel/carboplatin plus apatinib in advanced pulmonary sarcomatoid carcinoma: A case series and review of the literature
por: Kong, Feng-Wei, et al.
Publicado: (2020)

Apatinib Mesylate in the treatment of advanced progressed lung adenocarcinoma patients with EGFR-TKI resistance —A Multicenter Randomized Trial
por: Fang, Ping, et al.
Publicado: (2019)

Evaluation of second-line apatinib plus irinotecan as a treatment for advanced gastric adenocarcinoma or gastroesophageal conjunction adenocarcinoma: a prospective, multicenter phase II trial
por: Qu, Jinglei, et al.
Publicado: (2023)

S-1 plus apatinib as first-line palliative treatment for stage IVB gastroesophageal junction adenocarcinoma: A case report and review of the literature
por: Zhang, Chu, et al.
Publicado: (2020)

Efficacy of the Low Dose Apatinib plus Chemotherapy on Advanced Gastric Carcinoma
por: Gao, Shen, et al.
Publicado: (2022)

Combination therapy of apatinib with icotinib for primary acquired icotinib resistance in patients with advanced pulmonary adenocarcinoma with EGFR mutation
por: Xia, Pinghui, et al.
Publicado: (2018)

Salvage treatment with apatinib for advanced non-small-cell lung cancer
por: Song, Zhengbo, et al.
Publicado: (2017)

Efficacy and safety of camrelizumab plus apatinib as second-line treatment for advanced squamous non-small cell lung cancer
por: Gao, Guanghui, et al.
Publicado: (2022)

Multiple-dose up-titration study to evaluate the pharmacokinetics, safety and antitumor activity of apatinib in advanced gastric adenocarcinoma
por: Wang, Yonggang, et al.
Publicado: (2022)

Combination Use of Tegafur and Apatinib as First-Line Therapy in Treatment of Advanced Gastric Cancer: A Single-Blinded Randomized Study
por: Li, Chaofeng, et al.
Publicado: (2020)

Successful apatinib treatment for advanced clear cell renal carcinoma as a first-line palliative treatment: A case report
por: Wei, Hang-Ping, et al.
Publicado: (2022)

Clinical efficacy and safety of apatinib in patients with advanced colorectal cancer as the late-line treatment
por: Liao, Xiaoli, et al.
Publicado: (2018)

The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706)
por: Zhang, Zhonghan, et al.
Publicado: (2019)

Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first‐line treatment of advanced esophageal squamous cell carcinoma
por: Zhang, Bo, et al.
Publicado: (2020)

Clinical Effect of Apatinib Mesylate Tablets Combined with Paclitaxel Concurrent Radiotherapy and Chemotherapy in the First-Line Treatment of Locally Advanced Nasopharyngeal Carcinoma
por: Zhan, Dechao, et al.
Publicado: (2022)

Neoadjuvant apatinib plus S-1 in locally advanced pulmonary adenocarcinoma: A case report and review of the literature
por: Zhang, Chu, et al.
Publicado: (2020)

Efficacy and Safety of Apatinib Plus Vinorelbine in Patients With Wild-Type Advanced Non–Small Cell Lung Cancer After Second-Line Treatment Failure: A Nonrandomized Clinical Trial
por: Zhang, Xiangyu, et al.
Publicado: (2020)

Apatinib combined with PD-1 antibody for third-line or later treatment of advanced gastric cancer
por: Cui, Qingli, et al.
Publicado: (2022)

Apatinib is effective for treatment of advanced hepatocellular carcinoma
por: Kong, Yinlong, et al.
Publicado: (2017)

Apatinib as an alternative therapy for advanced hepatocellular carcinoma
por: Zhang, Xi-Hao, et al.
Publicado: (2020)

A Study Of Efficacy And Safety With Apatinib Or Apatinib Combined With Chemotherapy In Recurrent/advanced Ovarian Cancer Patients
por: Yang, Mi, et al.
Publicado: (2019)

Complete remission of advanced lung adenocarcinoma with first-line pembrolizumab monotherapy: Two case reports
por: Gohara, Kazuki, et al.
Publicado: (2021)

Efficacy of the low dose apatinib plus deep hyperthermia as third-line or later treatment in HER-2 negative advanced gastric cancer
por: Han, Guohu, et al.
Publicado: (2023)

A phase II study of antiangiogenic therapy (Apatinib) plus chemotherapy as second‐line treatment in advanced small cell lung cancer
por: Xu, Yinghui, et al.
Publicado: (2022)

Long-term progression-free survival of third-line apatinib in lung squamous cell carcinoma
por: Li, Xiaofen, et al.
Publicado: (2018)

A randomized phase 2 trial of apatinib vs observation as maintenance treatment following firstline induction chemotherapy in extensive stage small cell lung cancer
por: Luo, Hao, et al.
Publicado: (2019)

Effectiveness and safety of low‐dose apatinib in advanced gastric cancer: A real‐world study
por: Du, Yingying, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_669p8t8e02ngqtbkb5rf0cj9ia